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Abstract 17 
Development of high-concentration antibody formulations for subcutaneous administration 18 
remains challenging. Recently, a precipitation–redissolution method was proposed to prepare 19 
suspensions or precipitates of salt-dissociable protein–poly(amino acid) complexes. To elucidate the 20 
utility of this method for protein therapy, we investigated the feasibility of a precipitation–21 
redissolution method using poly(amino acid) for high-concentration antibody formulation. 22 
Omalizumab and adalimumab formulations of 150 mg/mL could be prepared using poly-L-glutamic 23 
acid (polyE) from low-concentration stock solutions. Enzyme-linked immunosorbent assay (ELISA), 24 
circular dichroism (CD), and size exclusion chromatography (SEC) revealed that the formation of 25 
antibody–polyE complex and precipitation–redissolution process did not significantly affect the 26 
immunoreactivity or secondary structure of the antibodies. The precipitation–redissolution method 27 
was less time-consuming and more effective than lyophilization–redissolution, evaporation–28 
redissolution, and ultrafiltration from the viewpoint of final yield. Scalability was confirmed from 29 
400 µL to 1.0 L. The general toxicity and pharmacokinetic profiles of the antibody–polyE complex 30 
formulations were similar to those of conventional antibody formulations. These results suggested 31 
that the precipitation–redissolution method using poly(amino acid) has great potential as a 32 
concentration method for antibody formulation and medicinal use. 33 
 34 
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CD, circular dichroism; ELISA, enzyme-linked immunosorbent assay; FcεRIα, high-affinity 41 
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horseradish peroxidase; IgE, immunoglobulin E; IgG, immunoglobulin G; MOPS, 3-(N-43 
morpholino)propanesulfonic acid; pI, Isoelectric point; polyE, poly-L-glutamic acid; PPC, protein–44 
polyelectrolyte complex; SEC, size exclusion chromatography; TMB, 3,3',5,5'-tetramethylbenzidine; 45 
TNF-α, tumor necrosis factor α; Tris, Tris(hydroxymethyl)aminomethane 46 
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Introduction 47 
Monoclonal antibodies have generated considerable interest as biopharmaceuticals over the 48 
past two decades because of their high target specificity and biocompatibility. At present, over 20 49 
types of monoclonal antibody have been approved by the US Food and Drug Administration1 and 50 
used for several types of disease, such as cancer and autoimmune diseases.2–5 Despite advances in 51 
antibody drug development, the routes of administration for these antibodies remain challenging. 52 
The major route of delivery for antibodies has been intravenous administration due to the high 53 
bioavailability.6 In contrast, subcutaneous administration has been in great demand as an alternative 54 
route that allows at-home administration by patients and improves compliance rates.7–10 However, 55 
the desirable concentration of antibodies for subcutaneous administration is usually above 100 56 
mg/mL with a volume limitation of 1.5 mL.9, 10 57 
Several methods have been developed to obtain high-concentration protein solutions that 58 
would enable proteins to be used in formulations, for example with additives such as arginine or 59 
other amino acids,11, 12 ultrafiltration,13 gelation,14 crystallization,15 liquid–liquid phase separation,16 60 
and spray drying.6, 17 However, these methods are still time-consuming and costly. Methods for the 61 
suspension or precipitation of protein have also been reported for use in concentrated protein 62 
formulations.18, 19 If the precipitates of protein can be fully resolubilized by the simple method, such 63 
precipitates can be used as concentrated protein solutions. Recently, we have demonstrated the 64 
complex precipitation–redissolution method with poly(amino acid) as a precipitant.20 Briefly, 65 
charged polyelectrolytes, including poly-L-lysine and poly-L-glutamic acid, interact strongly with 66 
complementary charged proteins through multiple electrostatic interactions, resulting in the 67 
formation of a protein–polyelectrolyte complex (PPC),20–26 which can often be precipitated 68 
depending on the experimental conditions, such as pH, ionic strength, and stoichiometric ratio.24, 27, 69 
28
 PPC precipitates are then redissolved by the addition of buffer with high ionic strength such that 70 
the final concentration reaches 150 mM, which corresponds to physiological conditions.20, 28, 29 This 71 
simple system has been applied successfully for several types of therapeutic protein, including 72 
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enzymes, antibodies, and peptide hormones.20 However, the utility of this precipitation–redissolution 73 
method for protein therapy is still unclear. 74 
In this study, we demonstrated the feasibility of the complex precipitation–redissolution 75 
method using poly(amino acid) for high-concentration antibody formulation. As described below, 76 
antibody formulations with concentrations over 100 mg/mL of adalimumab for autoimmune disease 77 
and omalizumab for allergic asthma could be prepared by addition of poly-L-glutamic acid (polyE). 78 
The formation of antibody−polyE complex and precipitation–redissolution processes did not 79 
significantly change the immunoactivity or secondary structure of the antibodies, and did not result 80 
in undesirable aggregation. Comparison of time required, yield, and aggregate ratio indicated that 81 
the precipitation–redissolution method was more effective for application than the conventional 82 
concentration methods, including lyophilization–redissolution, evaporation–redissolution, and 83 
ultrafiltration. The precipitation–redissolution method was successfully performed from a scale of 84 
400 µL to 1.0 L, indicating that this method could be scaled up to 2500-fold. Finally, the general 85 
toxicity and pharmacokinetic profiles of the antibody–polyE complex formulation were similar to 86 
those of conventional antibody formulations. These results suggested that this simple method 87 
represents a new strategy for preparing high-concentration antibody formulations, and we expect that 88 
this method and complex formulations would be applicable for medicinal use. 89 
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Experimental Section 90 
Materials 91 
Adalimumab was obtained from transfected Chinese hamster ovary (CHO) cell cultures and 92 
purified on a protein-A column. Omalizumab was purchased from Novartis Pharma KK (Tokyo, 93 
Japan) and purified on a protein-A column to remove the additives. Citrate, sodium chloride (NaCl), 94 
sodium phosphate, and potassium chloride (KCl) were from Kanto Chemical Co., Inc. (Tokyo, 95 
Japan). Polysorbate 20 was from Wako Pure Chemical. Ind., Ltd. (Osaka, Japan). 3-(N-96 
morpholino)Propanesulfonic acid (MOPS) and Blocking One were from Nacalai Tesque, Inc. 97 
(Kyoto, Japan). Tris(hydroxymethyl)aminomethane (Tris) was from Bio-Rad Laboratories (Hercules, 98 
CA). Biotinylated anti-human IgG monoclonal antibody, rat IgG, and poly-L-glutamic acid sodium 99 
salt with average molecular weights of 3000 – 15000 Da (polyE1) and 50000 – 100000 Da (polyE2) 100 
were from Sigma Chemical Co. (St. Louis, MO). Human IgE was from Abcam (Cambridge, MA). 101 
Biotinylated anti-human IgE monoclonal antibody was from Miltenyi Biotec GmbH (Bergisch 102 
Gladbach, Germany). Human tumor necrosis factor α (TNF-α) was from Gibco Life Technologies 103 
Ltd. (Grand Island, NY). Human high-affinity immunoglobulin epsilon receptor subunit alpha 104 
(FcεRIα) was from Sino Biological Inc. (Beijing, China). Streptavidin-labeled horseradish 105 
peroxidase (Avidin-HRP) was from Thermo Fisher Scientific (Waltham, MA). 3,3',5,5'-106 
Tetramethylbenzidine (TMB) was from KPL (Gennep, the Netherlands). Human IgG1 Therapeutic 107 
EIA Kit was from Cayman Chemical Co. (Ann Arbor, MI). Sucrose was from Dai-Nippon Meiji 108 
Sugar Co., Ltd. (Tokyo, Japan). L-Histidine hydrochloride was from Mitsubishi Tanabe Pharma Co. 109 
(Osaka, Japan). L-Histidine was from Kyowa Hakko Bio Co., Ltd. (Tokyo, Japan). Glucose 50% 110 
injection was from Terumo Co. (Tokyo Japan). These chemicals were of high-quality analytical 111 
grade and were used as received. 112 
 113 
Preparation of antibody–poly(amino acid) complex and redissolution 114 
The procedure of precipitation and redissolution of antibody−polyE1 complex was described 115 
as follows. Step 1: The antibody stock solutions containing low (1.0 mg/mL) and high (30 mg/mL) 116 
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concentration antibodies in 10 mM buffer (MOPS at pH 6.5, for adalimumab; citrate at pH 5.5 for 117 
omalizumab) were prepared. Step 2: Aliquots of 200 µL of various concentrations of polyE1 in 10 118 
mM buffer (MOPS at pH 6.5, for adalimumab; citrate at pH 5.5 for omalizumab) were mixed with 119 
aliquots of 200 µL antibody stock solution in the same buffer. Step 3: The samples of 120 
antibody−polyE mixture were centrifuged at 1000 × g for 3 minutes at 25oC. Step 4: The supernatant 121 
of 370 µL was removed and precipitates were resuspended by vortexing. The nominal value of the 122 
samples was 30 µL. Step 5: 10 µL of 600 mM NaCl in 10 mM buffer was added. The concentrations 123 
of antibodies for each step were determined from the absorbance at 280 nm using a spectrometer 124 
(SpectraMax Plus384; Molecular Devices Co., Ltd., Sunnyvale, CA). The immnoreactivity, 125 
secondary structure, and aggregation ratio were determined as described below. 126 
In addition to the above original scale experiments (400 µL), both 50-fold scale up (20 mL; 127 
medium scale) and 2500-fold scale up (1.0 L; large scale) experiments were performed. Table 3 128 
shows the volumes of these scales at Step 2. A concentration of 0.2 mg/mL polyE1 solution was 129 
mixed with 2.0 mg/mL adalimumab solution, and then precipitation–redissolution procedures were 130 
performed as described above. It is note that the final concentration of antibody at Step 5 is five 131 
times higher than that at Step 1. The containers and centrifuges used for each scale were 1.5 mL 132 
centrifuge tubes (MS-4215M; Sumitomo Bakelite Co., Ltd., Tokyo, Japan) and Kubota 3740 for 133 
mini-scale, 50 mL centrifuge tubes (430829; Corning Inc., Corning, NY) and Kubota 5220 for 134 
medium-scale, and 1 L Nalgene Polycarbonate Centrifuge Bottles (3122-1010; Thermo Fisher 135 
Scientific Inc., Waltham, MA) and Kubota 9900 for large-scale. All centrifuges were purchased 136 
from Kubota Co. (Tokyo, Japan). 137 
 138 
Concentration of antibody solutions by several methods 139 
To compare the efficiencies of the concentration methods, 150 mg/mL omalizumab and 140 
adalimumab solutions were prepared by the following methods. i) Precipitation–redissolution: 250 141 
µL of 0.15 mg/mL polyE1 in 10 mM buffer (MOPS, pH 6.5, for adalimumab; citrate, pH 5.5 for 142 
omalizumab) and 250 µL of 30 mg/mL antibodies in same buffer. The samples of antibody−polyE 143 
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mixture were centrifuged at 1000 × g for 3 minutes at 25oC. 462.5 µL of supernatant was removed 144 
and 12.5 µL of 600 mM NaCl in 10 mM buffer was added. The final volume of the concentrated 145 
antibodies was 50 µL. ii) Lyophilization−redissolution: 250 µL of 30 mg/mL antibodies in 10 mM 146 
buffer were added to vials and frozen onto a pre-cooled shelf (Drying Chamber DRC-1100; Tokyo 147 
Rikakikai Co., Ltd., Tokyo, Japan) at -40 oC for 2 hours. Subsequently, the frozen samples were 148 
primary dried at -20 oC for 12 hours, and were secondary dried at 25 oC for 4 hours under 0.67 Pa. 149 
After lyophylization, 50 µL of 10 mM buffer were added to the vials to redissolve the lyophilized 150 
cakes. iii) Evaporation−redissolution: 250 µL of 30 mg/mL antibodies in 10 mM buffer were added 151 
to tubes and evaporated in a rotatory evaporator (Centrifugal vaporizer CVE-100D; Tokyo 152 
Rikakikai). After evaporation,  50 µL of 10 mM buffer were added to the tube to redissolve the 153 
cakes. iv) Ultrafiltration: 250 µL of 30 mg/mL antibodies in 10 mM buffer were put into an 154 
ultrafiltration unit with a 50 kDa cut-off (UFC5050; Millipore Co., Ltd., Billerica, MA) and 155 
centrifuged at 14000 × g at 4°C until the volume was decreased to 50 µL. The time required, final 156 
concentration, and aggregation ratio were determined as described below. 157 
 158 
Immunoassay 159 
The immunoreactivities of omalizumab were measured by competitive enzyme-linked 160 
immunosorbent assay (ELISA) to confirm structural integrity of redissolved antibody. The wells of 161 
96-well ELISA microplates (Sumitomo Bakelite Co., Ltd., Tokyo, Japan) were coated with human 162 
FcεRIα, and the plates were incubated at 4°C overnight. The wells were washed a total of five times 163 
by addition of washing buffer containing 24.8 mM Tris, 136.9 mM NaCl, 2.7 mM KCl, and 0.1% 164 
polysorbate 20 (pH 7.4). The wells were then blocked with Blocking One at room temperature for 1 165 
hour. After washing of the wells, solutions containing human IgE at a constant concentration and 166 
omalizumab of different concentrations were added to the wells and incubated at room temperature 167 
for 1 hour. After washing of the wells, 100 µL of biotinylated anti-human IgE monoclonal antibody 168 
was added to each well and plates were incubated at room temperature for 1 hour. After washing of 169 
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the wells, 100 µL of streptavidin-labeled horseradish peroxidase was added to each well and plates 170 
were incubated at room temperature for 30 minutes. After washing of the wells, 100 µL of TMB was 171 
added to each well and plates were incubated at room temperature for more than 15 minutes. Finally, 172 
100 µL of 0.1% HCl was added and the absorbance at 450 nm was determined using a microplate 173 
reader (SpectraMax Plus384; Molecular Devices). 174 
The immunoreactivities of adalimumab were measured by ELISA. Two types of adalimumab 175 
with or without precipitation−redissolution method were used, as described above. The wells of 176 
polystyrene 96-well ELISA microplates were coated with human TNF-α, and the plates were 177 
incubated at 4°C overnight. After washing of the wells, Blocking One were added and plates were 178 
incubated at room temperature for 1 hour. After washing of the wells, 100 µL of adalimumab 179 
solutions with or without precipitation−redissolution process of different concentrations were added 180 
to the wells and plates were incubated at room temperature for 1 hour. After washing of the wells, 181 
100 µL of biotinylated anti-human IgG monoclonal antibody was added to each well and plates were 182 
incubated at room temperature for 1 hour. Subsequent procedures were as described above. 183 
 184 
Circular dichroism 185 
Circular dichroism (CD) experiments were performed using a spectropolarimeter (J-720; 186 
Japan Spectroscopic Co., Ltd., Tokyo, Japan). Two types of antibodies with or without 187 
precipitation−redissolution method were used, as described above. The samples containing 1.0 188 
mg/mL antibodies in 10 mM buffer were added to a 1-mm path length quartz cuvette, and then CD 189 
spectra of antibodies were measured at 25°C. Scans were taken from 195 to 250 nm at a rate of 100 190 
nm/min with a sample interval of 0.2 nm, 0.25 s response, and 1.0 nm bandwidth. 50 scans were 191 
averaged. Obtained far-UV CD spectra were plotted in the wavelength range of 210 – 250 nm 192 
because of the large noise below 210 nm. The CD spectra of the samples were corrected by 193 
subtracting the corresponding spectra of the buffers in the absence of antibodies. 194 
 195 
Size exclusion chromatography (SEC) 196 
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Two types of antibodies with or without precipitation−redissolution method were used, as 197 
described above. The samples containing 1.0 mg/mL antibodies in 10 mM buffer were centrifuged at 198 
14000 × g for 10 minutes, and then the supernatant was analyzed by SE-HPLC. The analysis was 199 
performed on an SEC column (Yarra 3u SEC-3000; Phenomenex Inc., Torrance, CA) on the HPLC 200 
system (LC-20A; Shimadzu Corp., Kyoto, Japan) at a constant flow rate of 0.5 mL/min. The mobile 201 
phase consisted of 100 mM sodium phosphate buffer and 0.5 M NaCl (pH 6.8). 202 
 203 
General toxicity test 204 
We evaluated general toxicity tests using two types of samples, IgG–polyE2 complex 205 
formulation and conventional IgG formulation as a control. Each formulation was prepared as 206 
described below. IgG−polyE2 complex formulation: Aliquots of 4.5 mL of 0.24 mg/mL polyE2, 207 
8.0% glucose, and 10 mM citrate (pH 5.0) were added to 4.5 mL of 2.0 mg/mL IgG and 10 mM 208 
citrate (pH 5.0) aseptically. The samples of antibody−polyE mixture were centrifuged at 1000 × g 209 
for 3 minutes at 25°C. 8.1 mL of supernatant was removed and precipitates were resuspended by 210 
vortexing. The nominal value of the samples was 900 µL containing 10 mg/mL IgG, 1.2 mg/mL 211 
polyE2, 4.0 % glucose, 10 mM citrate (pH 5.0). Conventional IgG formulation: Aliquots of 500 µL 212 
of 10 mg/mL IgG, 4.0 % glucose, 10 mM citrate (pH 5.0) was prepared. 213 
Five-week-old Crl:CD (SD) rats were from Charles River Laboratories Japan, Inc. 214 
(Kanagawa, Japan). The samples were injected subcutaneously into the backs of six rats in two 215 
groups at 50 mg/kg (333 nmol/kg). The body weights of the rat were measured for 0 – 14 days. 216 
Weight checks of the organs (heart, lung, liver, spleen, and kidney), pathology assessment, and 217 
blood test were performed for 1 and 2 weeks after injection. In the pathology assessment, the above 218 
organs and administration site were assessed. In the blood test, the following items were measured: 219 
white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), 220 
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular 221 
hemoglobin concentration (MCHC), platelets (PLT), activated partial thromboplastin time (APTT), 222 
prothrombin time (PT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine 223 
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aminotransferase (ALT), lactase dehydrogenase (LDH), total bilirubin (TB), total protein (TP), 224 
albumin (ALB), total cholesterol (TC), triglyceride (TG), phospholipid (PL), glucose (GLC), blood 225 
urea nitrogen (BUN), creatinine (CRE), inorganic phosphorus (Pi), calcium (Ca), sodium (Na), 226 
potassium (K), and chlorine (Cl).  227 
 228 
Pharmacokinetic profile 229 
We evaluated pharmacokinetic studies using two types of samples, omalizumab−polyE2 230 
complex formulation and conventional omalizumab formulation as a control. Each formulation was 231 
prepared as described below. Omalizumab−polyE2 complex formulation: Aliquots of 2.5 mL of 0.24 232 
mg/mL polyE2, 8.0% glucose, and 20 mM citrate (pH 5.5) were added to 2.5 mL of 2.0 mg/mL 233 
omalizumab and 20 mM citrate (pH 5.5) aseptically. The samples of antibody−polyE mixture were 234 
centrifuged at 1000 × g for 3 minutes at 25°C. 4.5 mL of supernatant was removed and precipitates 235 
were resuspended by vortexing. The nominal value of the samples was 500 µL containing 10 mg/mL 236 
omalizumab, 1.2 mg/mL polyE2, 4.0 % glucose, 20 mM citrate (pH 5.5). Conventional omalizumab 237 
formulation: Aliquots of 500 µL of 10 mg/mL omalizumab, 10.4% sucrose, 0.20% L-histidine 238 
hydrochloride, 0.13% L-histidine, and 0.04% polysorbate 20 was prepared. Sterile syringes were 239 
filled with the samples. Each sample, conventional, and complex formulation of omalizumab was 240 
injected subcutaneously into the backs of three rats at 10 mg/kg (66.7 nmol/kg), and the animals 241 
were kept in cages for 0 – 22 days. Blood was collected from the tail vein at 0 – 22 days after 242 
injection. Finally, blood concentration of omalizumab was measured using a Human IgG1 243 
Therapeutic EIA Kit (Cayman Chemical Co., Ann Arbor, MI). All animal experiments were 244 
approved by the institutional animal care and use committee of Terumo Corp. before the 245 
experiments. 246 
Page 11 of 32 Journal of Pharmaceutical Sciences
 12 
Results 247 
Preparation of high-concentration antibody solution by the precipitation–redissolution method 248 
Previously, we reported a precipitation–redissolution method using poly(amino acid), which 249 
enables the preparation of salt-dissociable precipitates of protein–poly(amino acid) complexes.20 To 250 
evaluate the efficiency of antibody concentration by the precipitation–redissolution method, we 251 
selected two antibody drugs: adalimumab (pI = 8.7; for autoimmune disease) and omalizumab (pI 252 
=7.6; for allergic asthma). Anionic poly-L-glutamic acid with average molecular weight of 3000 – 253 
15000 Da (polyE1) was selected for cationic antibodies at pH 5.5 – 6.5, because protein–poly(amino 254 
acid) complexes were formed only when poly(amino acid) had a charge complementary to that of 255 
the protein at experimental pH. Two types of stock solution containing low (1.0 mg/mL) or high (30 256 
mg/mL) concentrations of antibodies were mixed with the polyE1 solutions. The yield of antibody 257 
under the milder condition (1,000 g for 3 minutes at 25oC) was identical to that under the harder 258 
condition (15,000 g for 20 minutes at 25oC). Thus, the centrifugation condition was selected at 1,000 259 
g for 3 minutes at 25oC in this study. Figure 1 shows the final concentration of antibodies at Step 5. 260 
In Figure 1A, final concentration
 
of antibodies increased sharply with increasing concentration of 261 
polyE1, and reached a plateau at around 0.05 eq., which was consistent with the previous report.20 262 
Similar profiles were observed even at high concentration of stock solution (Figure 1B); final 263 
concentration values of omalizumab and adalimumab reached about 150 mg/mL at 0.05 eq. The 264 
yields of these antibodies were also about 100% even at high protein concentration (150 mg/mL) as 265 
well as low concentration (5 mg/mL). 266 
We next characterized the activity and structure of the redissolved antibodies. As shown in 267 
Figures 2A and 2B, the immunoreactivities of redissolved omalizumab and adalimumab were 268 
identical to those of native antibodies; the 50% inhibitory concentration values (IC50) of omalizumab 269 
and the 50% effective concentration values (EC50) of adalimumab were equivalent to those without 270 
polyE1 (Table 1, Figure 2A,B). Thus, the activities of the antibodies were not altered by the 271 
concentration and redissolution process. In addition, far-UV circular dichroism (CD) spectra of 272 
redissolved antibodies were identical to those of the native antibodies (Figure 2C,D), although 273 
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slight changes were observed in the far-UV CD spectra of adalimumab at 218 nm. These results 274 
suggested that the secondary structure of the antibodies were significantly maintained even in the 275 
redissolved state. Furthermore, SEC analysis indicated that the soluble aggregates were not 276 
increased in the redissolved antibody solutions (Figure 2E,F). These results suggested that 277 
redissolved antibodies retained the original activity, structure, and aggregation properties. 278 
 279 
Feasibility studies of precipitation–redissolution method 280 
We performed feasibility studies of the precipitation–redissolution method using poly(amino 281 
acid) to confirm its utility for pharmaceutical applications. First, the efficiency of the precipitation–282 
redissolution method was compared to three conventional concentration methods, i.e., 283 
lyophilization–redissolution, evaporation–redissolution, and ultrafiltration. As expected, we obtained 284 
150 mg/mL antibody solutions by the precipitation–redissolution method (Table 2). On the other 285 
hand, the final concentrations of antibody solutions obtained by the conventional methods were 72.7 286 
– 136 mg/mL, suggesting that some antibody was lost in the concentration process in these methods. 287 
The time required for the precipitation–redissolution method was about 2 hours, which was shorter 288 
than those of lyophilization and evaporation (Table 2). Furthermore, SEC analysis revealed that 289 
soluble aggregates did not increase in the concentrated antibody solutions prepared by the 290 
precipitation–redissolution method and ultrafiltration, but increased in those prepared by 291 
lyophilization and evaporation (Table 2). These results suggested that the precipitation–redissolution 292 
method is a good alternative to the well-known concentration methods. 293 
To examine whether the precipitation–redissolution method could be scaled up, we prepared 294 
10 mg/mL adalimumab from 2.0 mg/mL adalimumab by the addition of 0.1 mg/mL polyE1 at three 295 
different scales−original-scale (400 µL), 50-fold scale up (20 mL; medium-scale), and 2500-fold 296 
scale up (1.0 L; large-scale). Similar to the original-scale, the adalimumab–polyE mixed solution 297 
formed a complex and was suspended immediately at the medium- (data not shown) and large-scales 298 
(Figure 3 Step 2) At the large scale, the complex was spontaneously precipitated almost completely 299 
in 2 hours at Step 2. After centrifugation (Step 3), the supernatant was removed and resuspended 300 
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by mild agitation (Step 4). Finally, the suspension was fully dissolved by the addition of NaCl in the 301 
same buffer (Step 5). ELISA and SEC analysis revealed that the immunoreactivities and the amounts 302 
of soluble aggregates of redissolved adalimumab at medium and large scales were similar to those at 303 
the original-scale (Table 3), suggesting that the properties of redissolved antibody were independent 304 
of the scale. Thus, we confirmed that the precipitation–redissolution method could be scaled up by 305 
2500-fold. 306 
Finally, to test the potential of antibody–poly(amino acid) complexes for medicinal use, 307 
general toxicity tests of the antibody–poly(amino acid) complex suspension (Step 4) were performed. 308 
Anionic poly-L-glutamic acid with average molecular weight of 50000 – 100000 Da (polyE2) was 309 
selected because we speculated that poly(amino acids) with larger molecular weight would have 310 
longer blood half-lives and stronger influence.30 In addition, we selected rat IgG (pI ≈ 7.0) to avoid 311 
immune reaction in rats. Suspensions of the complex containing 10 mg/mL rat IgG and 1.2 mg/mL 312 
polyE2 (Step 4) were prepared by the precipitation–redissolution method, and then injected 313 
subcutaneously into rats at 50 mg/kg (333 nmol/kg). Comparison of administration of conventional 314 
IgG formulation and IgG–polyE2 complex formulation indicated no significant difference in rat 315 
body weight or the weights of several organs (heart, lung, liver, spleen, and kidney) between the two 316 
groups (Figure 4A,B). In addition, no significant differences in pathological findings or blood 317 
composition were observed between the two groups (data not shown). These results suggested that 318 
antibody–polyE complexes did not have general toxicity in these experimental animals. Furthermore, 319 
we performed pharmacokinetic analysis to compare the behaviors of the conventional omalizumab 320 
and omalizumab–polyE2 complex formulation in blood. Figure 4C shows the plasma concentration 321 
of omalizumab–time curve in rats after subcutaneous administration. The curve of omalizumab–322 
polyE2 complex (Step 4) corresponded to that of the conventional omalizumab. These results 323 
indicated that the antibody–polyE complex formulation did not affect the bioavailability of the 324 
therapeutic antibody. 325 
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Discussion 326 
High-concentration (> 100 mg/mL) antibody formulations are indispensable for 327 
subcutaneous administration because of the limitation of injection volume (typically 1.5 mL).9, 10 As 328 
demonstrated above, 150 mg/mL antibody formulations were successfully prepared from 30 mg/mL 329 
antibody solutions using the precipitation–redissolution method with poly(amino acid) (Figure 1). It 330 
is emphasized that the procedures involved in the precipitation–redissolution method are quite 331 
simple: (i) polyE is added to the antibody solution, resulting in precipitation of the antibody–polyE 332 
complex; (ii) the antibody–polyE precipitates can be suspended easily; (iii) the antibody–polyE 333 
complexes can be redissolved with saline solution. Note that the protein concentration was changed 334 
from 1.0 mg/mL to 30 mg/mL, indicating that the precipitation–redissolution method could be used 335 
for preparation of desirable concentrations of antibody formulations. In addition, the precipitation–336 
redissolution method would be applicable for several types of therapeutic protein, including 337 
enzymes, antibodies, and peptide hormones.20 338 
It is possible that quality of redissolved antibody formulation is comparable to the 339 
conventional antibody formulation. ELISA revealed that the immunoreactivity of redissolved 340 
antibodies was similar to that of native antibodies (Table 1, Figure 2A and 2B). Far-UV CD spectra 341 
suggested that the secondary structure of antibodies did not significantly change by the 342 
precipitation−redissolution process (Figure 2C and 2D). In addition, SEC analysis showed that 343 
soluble aggregates of redissolved antibodies were similar to those of the native antibodies (Figure 2E 344 
and 2F). Furthermore, pharmacokinetic profile of omalizumab/polyE complex formulation was 345 
similar to that of the conventional omalizumab formulation (Figure 4C). Although further 346 
investigation of structural and colloidal properties remains unclear, these in vitro and in vivo 347 
evaluations supported that the redissolved antibodies are likely to be applicable for protein therapy. 348 
Comparison with conventional concentration methods indicated significant advantages of the 349 
precipitation–redissolution method with regard to time required and yield (Table 2). The 350 
precipitation–redissolution method successfully prepared antibody solutions of about 150 mg/mL 351 
within 2 hours, whereas lyophilization–redissolution, evaporation–redissolution, and ultrafiltration 352 
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failed to reach this concentration (Table 2). Although visible aggregates were not observed in the 353 
adalimumab concentrated by the conventional methods, the final concentrations were lower than 150 354 
mg/mL. The loss of adalimumab in these methods were due to the unfavorable influences of these 355 
processes, such as adsorption to the container or ultrafiltration membrane31–34 or the generation of 356 
water-ice crystals at the periphery of the container.35 In contrast, the final concentrations of 357 
omalizumab obtained by the conventional methods were significantly lower than that achieved by 358 
the precipitation–redissolution method (Table 2), Visible aggregates were observed in the 359 
omalizumab solution during the concentration process, suggesting that the aggregates decreased the 360 
yield of concentrated omalizumab. Thus, the precipitation–redissolution method enables prompt and 361 
successful concentration of antibodies without soluble aggregates. 362 
The precipitation–redissolution method has another significant advantage with regard to 363 
scalability. The adalimumab solutions with different volume scale were successfully concentrated 5-364 
fold without loss of quality (Table 3). Interestingly, centrifugation is not always necessary to prepare 365 
highly concentrated antibody formulations on a large scale. As shown in Figure 3, the adalimumab–366 
polyE complex was formed and the solution was suspended immediately. The suspension began to 367 
precipitate spontaneously a few minutes later and precipitated almost completely within 2 hours 368 
(Step 2). The supernatant of the precipitation solution without centrifugation did not contain any 369 
antibody (data not shown). The volume of supernatant collected was 0.98 L, meaning that the 370 
theoretical maximum concentration of redissolved adalimumab was > 5-fold even without 371 
centrifugation. This is important for the application of the precipitation–redissolution method for 372 
industrialization, e.g., to reduce the costs associated with centrifuges. 373 
Poly(amino acids) are not listed on the Inactive Ingredient Search for Approved Drug 374 
Products of the US Food and Drug Administration, although poly(amino acids) have been used as 375 
biocompatible materials.36–39 Nevertheless, in vivo tests revealed that the general toxicity and 376 
pharmacokinetic profile of the antibody–polyE complex formulations were identical to those of the 377 
conventional antibody formulation (Figure 4). The antibody–polyE complex could be easily 378 
dissociated by saline solution; the salts at physiological ionic concentration (150 mM) shielded 379 
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the electrostatic interaction between antibody and polyE and then dissociated the precipitable 380 
complexes.28, 29 Accordingly, it was suggested that the suspension of antibody–polyE complex 381 
injected into rats was immediately dissolved to antibody and polyE at physiological ionic strength in 382 
the subdermal space. Therefore, we concluded that the high-concentration antibody–poly(amino 383 
acid) complex has biocompatibility for application in protein therapy. 384 
In summary, this study indicated the feasibility of the precipitation–redissolution method for 385 
preparation of antibody–poly(amino acid) complex formulations. This simple, quick, and scalable 386 
method allows the formation of high-concentration protein solutions without loss of structure or 387 
function. More importantly, antibody–polyE complex formulations have the same level of 388 
biocompatibility as conventional antibody formulations. Due to its several advantages, the 389 
precipitation–redissolution method could be beneficial in medical applications. We expect that 390 
protein–poly(amino acid) complex formulations prepared by this method could be used in protein 391 
therapy. 392 
 393 
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Table Legends 487 
Table 1. Immunoreactivities of redissolved antibodies 488 
 489 
Table 2. Comparison of the precipitation–redissolution method with conventional concentration 490 
methods 491 
 492 
Table 3. Scaling up of the precipitation–redissolution method for preparation of 10 mg/mL 493 
adalimumab from 2.0 mg/mL stock solution 494 
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Figure Legends 495 
 496 
Figure 1. Precipitation–redissolution profiles of antibodies by polyE1. Various concentrations of 497 
polyE1 were added to stock solutions containing 1.0 mg/mL (low) (A) or 30 mg/mL (high) (B) 498 
antibodyes in 10 mM buffer. The final concentrations of antibodies at Step 5 in the presence of 499 
polyE1 were measured. The final concentration of antibodies in the absence of polyE1 was lower 500 
than that of stock solution due to the dilution of precipitation–redissolution process. Closed circles, 501 
omalizumab; open circles, adalimumab. 502 
 503 
Figure 2. Characterization of omalizumab (A,C,E) and adalimumab (B,D,F) with or witout 504 
precipitation−redissolution method. (A,B) Binding curve of antibodies. dashed lines; native 505 
antibodies, open circles; low-concentration redissolved antibodies and closed circles; high-506 
concentration redissolved antibodies. (C,D) Far-UV CD spectra of antibodies. solid lines; native 507 
antibodies and dushed lines; high-concentration redissolved antibodies. (E,F) SEC chromatograms 508 
of antibodies, solid lines; native antibodies, dotted lines; low-concentration redissolved antibodies 509 
ans dushed lines; high-concentration redissolved antibodies, arrowhead; monomer peak and arrow; 510 
aggregate peak. 511 
 512 
Figure 3. Outline of precipitation–redissolution method for adalimumab at the scale of 1.0 L. 513 
Aliquots of 0.5 L of 0.2 mg/mL polyE1 solution in 10 mM MOPS (pH 6.5) was added to 0.5 L of 514 
stock solution containing 2.0 mg/mL adalimumab in the same buffer (Step 1), and antibody–polyE 515 
complex suspension was formed immediately (Step 2). After centrifugation (Step 3), 0.91 L of 516 
supernatant was removed and the precipitate was resuspended by mild agitation (Step 4) followed by 517 
addition of 0.01 L buffer containing NaCl (Step 5). 518 
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Figure 4. (A,B) General toxicity tests in rats; body weight of rats (A) and weight of organs (B). 519 
Conventional IgG formulation, closed symbols; IgG-polyE2 complex fomulation, open symbols. (C) 520 
Plasma concentration of omalizumab–time curve in rats after subcutaneous administration. 521 
Conventional omalizumab formulation, open circles; omalizumab–polyE2 complex formulation, 522 
closed circles. 523 
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Tables 1 
Table 1. Immunoreactivities of redissolved antibodies 2 
Antibody Concentration Activitycontrol ActivityStep5 
Omalizumab Low 3.99 (nM) a 3.92 (nM) a 
 
High 
 
3.77 (nM) a 
Adalimumab Low 327 (pM) b 321 (nM) b 
 
High 
 
309 (pM) b 
a
 50% inhibitory concentration. 3 
b
 50% effective concentration. 4 
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Table 2. Comparison of the precipitation–redissolution method with conventional concentration methods 5 
    Adalimumab Omalizumab 
 
Time Require Final concentration Aggregation peak ratio Final concentration Aggregation peak ratio 
Concentration method (hours) (mg/mL) (%) (mg/mL) (%) 
Precipitation–redissolution 2 151 9.67 154 3.98 
Lyophilization-redissolution 18 136 12.7 86.0 7.35 
Evapolation-redissolution 5 133 19.4 96.1 8.61 
Ultrafiltration 2 131 7.29 72.7 3.58 
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Table 3. Scaling up of the precipitation–redissolution method for preparation of 10 mg/mL adalimumab from 2.0 mg/mL stock solution 6 
Scale Final concentration Immunoreactivity Aggregate peak ratio 
  (mg/mL) (pM) (%) 
Mini (400 µL) 10.2 302 8.09 
Medium (20 mL) 10.1 317 8.42 
Large (1.0 L) 10.4 289 8.52 
 7 
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Figure 1. Precipitation–redissolution profiles of antibodies by polyE1. Various concentrations of polyE1 were 
added to stock solutions containing 1.0 mg/mL (low) (A) or 30 mg/mL (high) (B) antibodyes in 10 mM 
buffer. The final concentrations of antibodies at Step 5 in the presence of polyE1 were measured. The final 
concentration of antibodies in the absence of polyE1 was lower than that of stock solution due to the dilution 
of precipitation–redissolution process. Closed circles, omalizumab; open circles, adalimumab.  
79x120mm (300 x 300 DPI)  
 
 
Page 28 of 32Journal of Pharmaceutical Sciences
  
 
 
Figure 2. Characterization of omalizumab (A,C,E) and adalimumab (B,D,F) with or witout 
precipitation−redissolution method. (A,B) Binding curve of antibodies. dashed lines; native antibodies, open 
circles; low-concentration redissolved antibodies and closed circles; high-concentration redissolved 
antibodies. (C,D) Far-UV CD spectra of antibodies. solid lines; native antibodies and dushed lines; high-
concentration redissolved antibodies. (E,F) SEC chromatograms of antibodies, solid lines; native antibodies, 
dotted lines; low-concentration redissolved antibodies ans dushed lines; high-concentration redissolved 
antibodies, arrowhead; monomer peak and arrow; aggregate peak.  
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Figure 3. Outline of precipitation–redissolution method for adalimumab at the scale of 1.0 L. Aliquots of 0.5 
L of 0.2 mg/mL polyE1 solution in 10 mM MOPS (pH 6.5) was added to 0.5 L of stock solution containing 2.0 
mg/mL adalimumab in the same buffer (Step 1), and antibody–polyE complex suspension was formed 
immediately (Step 2). After centrifugation (Step 3), 0.91 L of supernatant was removed and the precipitate 
was resuspended by mild agitation (Step 4) followed by addition of 0.01 L buffer containing NaCl (Step 5).  
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Figure 4. (A,B) General toxicity tests in rats; body weight of rats (A) and weight of organs (B). 
Conventional IgG formulation, closed symbols; IgG-polyE2 complex fomulation, open symbols. (C) Plasma 
concentration of omalizumab–time curve in rats after subcutaneous administration. Conventional 
omalizumab formulation, open circles; omalizumab–polyE2 complex formulation, closed circles.  
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